Skip to main content
Kent Academic Repository

Latrophilins as Novel Biomarkers for Leukaemia Diagnostics. WO2016203031A1 2016

Vadim Sumbayev, Yuri Ushkaryov, Bernhard Gibbs (2016) Latrophilins as Novel Biomarkers for Leukaemia Diagnostics. WO2016203031A1 2016. WO2016203031A1. (doi:WO2016203031A1) (KAR id:53391)

PDF (Vadim Sumbayev, Yuri Ushkaryov (2016) “Latrophilins as Novel Biomarkers for Leukaemia Diagnostics” WO2016203031A1 US20180188253A1 EP3311166A1) Publisher pdf
Language: English


Download this file
(PDF/2MB)
[thumbnail of Vadim Sumbayev, Yuri Ushkaryov (2016) “Latrophilins as Novel Biomarkers for Leukaemia Diagnostics” WO2016203031A1 US20180188253A1 EP3311166A1]
Preview
Request a format suitable for use with assistive technology e.g. a screenreader
Official URL:
https://patents.google.com/patent/WO2016203031A1

Abstract

Leukaemia (blood/bone marrow cancer) affects over 250,000 people per year worldwide, with a potentially high mortality rate depending on the type of disease, age at onset and response to treatment–related toxicity. Since leukaemia affects a large number of children and elderly people, this discovery is crucially important for public health. High mortality rates can be, in part, ascribed to current treatments, which consist of aggressive chemotherapy and stem cell transplantation, and often do not result in effective remission of the disease. This is the result of a lack of understanding of the molecular mechanisms that allow malignant cells to escape host immune attack involving cytotoxic T lymphocytes and Natural Killer (NK) lymphoid cells. Our work led to a fundamental non-incremental breakthrough in understanding of the pathophysiology of leukaemia. We have recently discovered that acute myeloid leukaemia (AML) cells possess a unique biochemical pathway that allows these cells to escape the human body’s own anti-cancer immune defences. This pathological immunoprotective pathway does not exist in healthy blood cells, but develops as a result of malignant transformation. Importantly we discovered a novel biomarker of AML, which unlike other known biomarkers is expressed only in malignant and not in healthy cells.

Item Type: Patent
DOI/Identification number: WO2016203031A1
Subjects: R Medicine
R Medicine > R Medicine (General) > R729 Types of medical practice > R729.5.G4 General practice
R Medicine > RC Internal medicine
R Medicine > RC Internal medicine > RC254 Neoplasms. Tumors. Oncology
R Medicine > RC Internal medicine > RC667 Diseases of the circulatory (cardiovascular) system
Divisions: Divisions > Division of Natural Sciences > Medway School of Pharmacy
Depositing User: Yuri Ushkarev
Date Deposited: 14 Dec 2015 14:23 UTC
Last Modified: 16 Feb 2021 13:32 UTC
Resource URI: https://kar.kent.ac.uk/id/eprint/53391 (The current URI for this page, for reference purposes)

University of Kent Author Information

Sumbayev, Vadim V..

Creator's ORCID: https://orcid.org/0000-0002-9404-5626
CReDIT Contributor Roles:

Ushkaryov, Yuri.

Creator's ORCID: https://orcid.org/0000-0002-5712-8297
CReDIT Contributor Roles:

Gibbs, Bernhard F.

Creator's ORCID:
CReDIT Contributor Roles:
  • Depositors only (login required):

Total unique views for this document in KAR since July 2020. For more details click on the image.